Please login to the form below

Not currently logged in


This page shows the latest Luxturna news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

to complete its acquisition of gene therapy specialist Spark Therapeutics and its new blindness treatment Luxturna.

Latest news

More from news
Approximately 6 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Cell and gene therapy Cell and gene therapy

    Cell and gene therapies are currently expensive to manufacture. We do not believe that recently marketed products, with US prices ranging from $373, 000 for Yescarta to $850, 000 for Luxturna,

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    therapy Luxturna was also approved in Europe late in the year. ... Novartis has a deal with Spark to market Luxturna in Europe, and is therefore at the forefront of not only the groundbreaking R&D behind cell and gene therapy, but is

  • Bluebird Bio: on the cusp of a gene therapy revolution Bluebird Bio: on the cusp of a gene therapy revolution

    drugs, Novartis’ Kymriah and Gilead/Kite’s Yescarta and Spark Therapeutics’ gene therapy Luxturna all reaching the market last year. ... Spark's Luxturna: already approved in the US, expected to gain EU approval by late 2018.

  • Health on instalment Health on instalment

    For example, the ophthalmic drug Luxturna, approved last year, costs $850, 000 per dose. ... For example, Luxturna maker Spark Therapeutics approached a commercial payer with a pay-for-performance option.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...